患者层面与医院层面预测因素与类风湿关节炎患者初始治疗模式的关联:一项全国队列研究结果
该回顾性队列研究纳入2018年5月1日至2023年4月1日英国新诊断的成年RA患者,分析一线csDMARD处方模式及其与个体和医院因素的关联。共15462例接受csDMARD治疗,57%接受MTX单药、14%接受MTX联合治疗作为一线方案。较高的DAS28与MTX单药(aOR 1.25)和MTX联合治疗(aOR 1.45)处方几率升高相关,非白种人合并症患者中较低。约20%的一线csDMARD处方变异归因于医院层面。
要点
- 57%新诊断RA患者一线接受MTX单药,14%接受MTX联合治疗,MTX是最常用药物。
- 较高DAS28与MTX单药(aOR 1.25)及MTX联合治疗(aOR 1.45)处方几率升高相关。
- 约20%的一线csDMARD处方变异归因于医院层面。
核心结论
- 在新发RA队列中,一线csDMARD治疗策略存在明显的个体层面和机构层面变异。
- 性别、种族、疾病活动和合并症(尤其是肺部疾病)与个体层面的差异相关。
研究设计与样本
- 回顾性队列研究,纳入2018年5月1日至2023年4月1日英国新诊断的成年RA患者。
- 使用调整后的多水平logistic回归(含随机效应)探索与不同一线csDMARD处方的关联,并考虑医院层面聚类。
主要发现
- 共识别15462例接受csDMARD治疗的RA患者,57%接受MTX单药、14%接受MTX联合治疗作为一线治疗。
- MTX是最常处方的药物,其次是HCQ和SSZ。
- 与未处方MTX相比,较高DAS28患者中MTX单药处方aOR为1.25(95%CI 1.22-1.29),MTX联合治疗aOR为1.45(95%CI 1.38-1.52)。
- 在非白种人合并症(肺部疾病、癌症、骨折和心脏病发作)患者中,MTX单药和联合治疗处方几率较低。
- 在接受MTX的患者中,与联合治疗相比,较高DAS28患者更可能接受单药治疗(aOR 1.08,95%CI 1.05-1.11),无肺部疾病患者单药治疗aOR为0.5(95%CI 0.44-0.56)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To update the first-line conventional synthetic DMARDs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the RA population, and identify individual and hospital factors associated with it. METHODS: This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018 to 1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering. RESULTS: We identified 15 462 RA patients who received csDMARD treatment. Overall, 57% received MTX monotherapy and 14% received MTX combination therapy as first-line treatment. MTX is the most frequently medication, following by HCQ and SSZ. Compared with non-MTX prescription, prescription of MTX monotherapy [adjusted odds ratio (aOR) 1.25 95% CI (1.22-1.29)] and MTX combination therapy [aOR 1.45 (1.38-1.52)] was significantly higher in patients with higher DAS28, but lower in the non-White individuals with comorbidities: lung disease, cancer, fracture and heart attack. Among those who received MTX, monotherapy is more likely be prescribed in patients with higher DAS28 [aOR 1.08 (1.05-1.11)] and without lung disease [aOR 0.5 (0.44-0.56)], compared with combination therapy. Around 20% of the variability in first-line csDMARD prescribing was attributed to the hospital level. CONCLUSION: In this cohort study of new-onset RA population, both individual- and institution-level variation in first-line csDMARD treatment strategy was evident. Gender, ethnicity, disease activity, and comorbidities, especially lung disease, were associated with disparities at the individual level.
引用
- Yang Z, Alveyn E, Russell M, et al. Association of patient- and hospital-level predictors with patterns of initial treatment in patients with rheumatoid arthritis: findings from a national cohort study. Rheumatology (Oxford). 2025. PMID: 39718801. doi:10.1093/rheumatology/keae717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。